BenchSci

Kosmos, the AI scientist — autonomous literature and data-analysis research runs.

The for-profit spinout commercializing nonprofit lab FutureHouse's scientific agents. Its flagship Kosmos runs autonomous research campaigns — iterating data analysis, literature search, and hypothesis generation across roughly 1,500 papers per run — and returns fully cited research reports. The Edison Platform took over FutureHouse's hosted literature agents, with the first Kosmos runs free for academic researchers.

AI-driven drug discovery on the Recursion OS platform.

Recursion is a clinical-stage, technology-enabled drug discovery company built around Recursion OS, which pairs one of biopharma's largest proprietary datasets with automated wet labs and machine learning for target and molecule discovery. Its LOWE interface lets scientists query the platform in natural language to find targets, generate compounds, and schedule experiments. It advances an internal pipeline and partners with pharma rather than selling self-serve software.

Generative AI drug discovery — the end-to-end Pharma.ai suite.

Insilico Medicine is a clinical-stage drug discovery company whose Pharma.ai suite applies generative AI across the pipeline: PandaOmics for target identification, Chemistry42 for de novo molecule design, and inClinico for clinical-trial outcome prediction. The cloud software is licensed to pharma, and the company says it serves 13 of the top 20 global drugmakers. It also runs its own internal pipeline of AI-discovered drug candidates.

AI agents that automate scientific literature research and discovery.

FutureHouse is a nonprofit AI-for-science lab building AI agents that automate steps of the research process. Its free FutureHouse Platform exposes specialized agents — including Crow, Falcon, Owl, and Phoenix — for literature search, synthesis, and chemistry, plus Kosmos, an 'AI Scientist' that runs autonomous multi-step analyses. The agents are available through a web app and an open API.